Contra-indicated in patients with active or suspected neoplasia; or with closed epiphyses. Increlex is contraindicated for intravenous administration.
- TRADE NAME: Increlex (Tercica)
- INDICATIONS: Growth failure in children with primary insulin growth factor 1 deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH
- CLASS: Hormone, polypeptide, Insulin-like growth factor (IGF)
- HALF-LIFE: 5.8 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
